David Lodge

Title: Innovator David Lodge: Pioneering Advances in GluR5 Receptor Research

Introduction: David Lodge is a distinguished inventor based in Indianapolis, IN, with a focus on the pharmacological modulation of the glutamate GluR5 receptor. With two patents to his name, he has made significant contributions to the field of drug discovery and development, particularly in pain management.

Latest Patents: His most recent patents include an assay for evaluating the affinity of compounds to the glutamate GluR5 receptor, which involves a hippocampal GluR5 receptor modulator. The innovative compound 2-amino-3-(3-hydroxy-5-tert-butylisoxazol-4-yl)propanoic acid (ATPA) is instrumental in measuring the binding affinity of chemical compounds to GluR5 receptors. Additionally, his research has revealed pharmacological agents such as selective antagonists for the GluR5 receptor, which hold promising potential for treating pain. Furthermore, novel decahydroisoquinoline derivatives identified in his work are recognized as selective GluR5 receptor antagonists, adding to the therapeutic arsenal against pain.

Career Highlights: David Lodge contributes his expertise to Eli Lilly and Company, where he plays a vital role in the research and development of pharmacological solutions. His work is at the forefront of advancing understanding in receptor biology and therapeutic interventions.

Collaborations: Throughout his career, Lodge has collaborated with notable colleagues such as David Bleakman and David R. Helton. These partnerships have fostered an environment of innovation and excellence, further enhancing the impact of their collective research efforts.

Conclusion: David Lodge exemplifies the spirit of innovation in the realm of pharmaceutical research. His work, focused on the GluR5 receptor, showcases the transformative potential of scientific inquiry and collaboration. As the field of pain management continues to evolve, Lodge's contributions are likely to serve as a foundation for future advancements.